FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4383199021> ?p ?o ?g. }

• W4383199021 abstract "Background: Almost all patients treated with androgen deprivation therapy (ADT) eventually develop castration-resistant prostate cancer (CRPC). Our research aims to elucidate the potential biomarkers and molecular mechanisms that underlie the transformation of primary prostate cancer into CRPC. Methods: We collected three microarray datasets (GSE32269, GSE74367, and GSE66187) from the Gene Expression Omnibus (GEO) database for CRPC. Differentially expressed genes (DEGs) in CRPC were identified for further analyses, including Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and gene set enrichment analysis (GSEA). Weighted gene coexpression network analysis (WGCNA) and two machine learning algorithms were employed to identify potential biomarkers for CRPC. The diagnostic efficiency of the selected biomarkers was evaluated based on gene expression level and receiver operating characteristic (ROC) curve analyses. We conducted virtual screening of drugs using AutoDock Vina. In vitro experiments were performed using the Cell Counting Kit-8 (CCK-8) assay to evaluate the inhibitory effects of the drugs on CRPC cell viability. Scratch and transwell invasion assays were employed to assess the effects of the drugs on the migration and invasion abilities of prostate cancer cells. Results: Overall, a total of 719 DEGs, consisting of 513 upregulated and 206 downregulated genes, were identified. The biological functional enrichment analysis indicated that DEGs were mainly enriched in pathways related to the cell cycle and metabolism. CCNA2 and CKS2 were identified as promising biomarkers using a combination of WGCNA, LASSO logistic regression, SVM-RFE, and Venn diagram analyses. These potential biomarkers were further validated and exhibited a strong predictive ability. The results of the virtual screening revealed Aprepitant and Dolutegravir as the optimal targeted drugs for CCNA2 and CKS2, respectively. In vitro experiments demonstrated that both Aprepitant and Dolutegravir exerted significant inhibitory effects on CRPC cells (p < 0.05), with Aprepitant displaying a superior inhibitory effect compared to Dolutegravir. Discussion: The expression of CCNA2 and CKS2 increases with the progression of prostate cancer, which may be one of the driving factors for the progression of prostate cancer and can serve as diagnostic biomarkers and therapeutic targets for CRPC. Additionally, Aprepitant and Dolutegravir show potential as anti-tumor drugs for CRPC." @default.
• W4383199021 created "2023-07-06" @default.
• W4383199021 creator A5004287621 @default.
• W4383199021 creator A5006962593 @default.
• W4383199021 creator A5021019207 @default.
• W4383199021 creator A5034471264 @default.
• W4383199021 creator A5058958720 @default.
• W4383199021 creator A5062517400 @default.
• W4383199021 creator A5065058975 @default.
• W4383199021 date "2023-07-05" @default.
• W4383199021 modified "2023-10-18" @default.
• W4383199021 title "Comprehensive analysis of the progression mechanisms of CRPC and its inhibitor discovery based on machine learning algorithms" @default.
• W4383199021 cites W1544564404 @default.
• W4383199021 cites W1578291413 @default.
• W4383199021 cites W1949146490 @default.
• W4383199021 cites W1966327575 @default.
• W4383199021 cites W1972675532 @default.
• W4383199021 cites W1975609403 @default.
• W4383199021 cites W2000968765 @default.
• W4383199021 cites W2004131109 @default.
• W4383199021 cites W2005958584 @default.
• W4383199021 cites W2013406919 @default.
• W4383199021 cites W2025622996 @default.
• W4383199021 cites W2040703771 @default.
• W4383199021 cites W2045612398 @default.
• W4383199021 cites W2051025382 @default.
• W4383199021 cites W2053484677 @default.
• W4383199021 cites W2067316851 @default.
• W4383199021 cites W2076159948 @default.
• W4383199021 cites W2082539078 @default.
• W4383199021 cites W2089707059 @default.
• W4383199021 cites W2098315492 @default.
• W4383199021 cites W2103959341 @default.
• W4383199021 cites W2113253187 @default.
• W4383199021 cites W2120292596 @default.
• W4383199021 cites W2131105131 @default.
• W4383199021 cites W2134069762 @default.
• W4383199021 cites W2134967712 @default.
• W4383199021 cites W2135046866 @default.
• W4383199021 cites W2141077390 @default.
• W4383199021 cites W2146512944 @default.
• W4383199021 cites W2149150781 @default.
• W4383199021 cites W2150169404 @default.
• W4383199021 cites W2298285788 @default.
• W4383199021 cites W2410928345 @default.
• W4383199021 cites W2610316990 @default.
• W4383199021 cites W2776697894 @default.
• W4383199021 cites W2911188335 @default.
• W4383199021 cites W2911362138 @default.
• W4383199021 cites W2913403432 @default.
• W4383199021 cites W2921877547 @default.
• W4383199021 cites W2948558658 @default.
• W4383199021 cites W2953641512 @default.
• W4383199021 cites W3003512840 @default.
• W4383199021 cites W3006590962 @default.
• W4383199021 cites W3081889500 @default.
• W4383199021 cites W3159177617 @default.
• W4383199021 cites W4205918537 @default.
• W4383199021 cites W4210254536 @default.
• W4383199021 cites W4283785449 @default.
• W4383199021 doi "https://doi.org/10.3389/fgene.2023.1184704" @default.
• W4383199021 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37476415" @default.
• W4383199021 hasPublicationYear "2023" @default.
• W4383199021 type Work @default.
• W4383199021 citedByCount "0" @default.
• W4383199021 crossrefType "journal-article" @default.
• W4383199021 hasAuthorship W4383199021A5004287621 @default.
• W4383199021 hasAuthorship W4383199021A5006962593 @default.
• W4383199021 hasAuthorship W4383199021A5021019207 @default.
• W4383199021 hasAuthorship W4383199021A5034471264 @default.
• W4383199021 hasAuthorship W4383199021A5058958720 @default.
• W4383199021 hasAuthorship W4383199021A5062517400 @default.
• W4383199021 hasAuthorship W4383199021A5065058975 @default.
• W4383199021 hasBestOaLocation W43831990211 @default.
• W4383199021 hasConcept C104317684 @default.
• W4383199021 hasConcept C119857082 @default.
• W4383199021 hasConcept C121608353 @default.
• W4383199021 hasConcept C150194340 @default.
• W4383199021 hasConcept C152724338 @default.
• W4383199021 hasConcept C2780192828 @default.
• W4383199021 hasConcept C2987395477 @default.
• W4383199021 hasConcept C41008148 @default.
• W4383199021 hasConcept C54355233 @default.
• W4383199021 hasConcept C60644358 @default.
• W4383199021 hasConcept C70721500 @default.
• W4383199021 hasConcept C8415881 @default.
• W4383199021 hasConcept C86803240 @default.
• W4383199021 hasConceptScore W4383199021C104317684 @default.
• W4383199021 hasConceptScore W4383199021C119857082 @default.
• W4383199021 hasConceptScore W4383199021C121608353 @default.
• W4383199021 hasConceptScore W4383199021C150194340 @default.
• W4383199021 hasConceptScore W4383199021C152724338 @default.
• W4383199021 hasConceptScore W4383199021C2780192828 @default.
• W4383199021 hasConceptScore W4383199021C2987395477 @default.
• W4383199021 hasConceptScore W4383199021C41008148 @default.
• W4383199021 hasConceptScore W4383199021C54355233 @default.
• W4383199021 hasConceptScore W4383199021C60644358 @default.
• W4383199021 hasConceptScore W4383199021C70721500 @default.
• W4383199021 hasConceptScore W4383199021C8415881 @default.
• W4383199021 hasConceptScore W4383199021C86803240 @default.

• next